Leap Therapeutics (LPTX) News Today $2.49 +0.03 (+1.22%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$2.43▼$2.6550-Day Range$1.30▼$2.8652-Week Range$1.24▼$10.20Volume118,092 shsAverage Volume186,620 shsMarket Capitalization$63.67 millionP/E RatioN/ADividend YieldN/APrice Target$17.30 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conferencefinance.yahoo.com - November 21 at 7:52 AMLeap Therapeutics (NASDAQ:LPTX) Price Target Cut to $12.00 by Analysts at Mizuhoamericanbankingnews.com - November 21 at 3:42 AMRaymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - November 14 at 2:08 PMLeap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 13 at 9:31 AMRecap: Leap Therapeutics Q3 Earningsbenzinga.com - November 13 at 9:31 AMLeap Therapeutics Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 9:31 AMLeap Therapeutics to Participate at Upcoming Investor Conferencesfinance.yahoo.com - September 5 at 6:06 PMHC Wainwright & Co. Maintains Leap Therapeutics (LPTX) Buy Recommendationmsn.com - August 15 at 6:09 PMBaird Maintains Leap Therapeutics (LPTX) Outperform Recommendationmsn.com - August 15 at 6:09 PMLeap Therapeutics (LPTX) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 15 at 7:59 AMLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 14 at 4:53 PMLeap Therapeutics Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 14 at 4:53 PMRaymond James Maintains Leap Therapeutics (LPTX) Outperform Recommendationmsn.com - July 14 at 12:41 AMLeap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patientsfinance.yahoo.com - July 12 at 9:07 AMLeap Therapeutics (LPTX) Price Target Increased by 876.00% to 24.89msn.com - July 6 at 11:33 PMLeap Therapeutics (LPTX) Receives a Buy from Raymond Jamesmarkets.businessinsider.com - June 23 at 12:27 PMLeap Therapeutics (NASDAQ:LPTX) Given New $17.00 Price Target at Raymond Jamesmarketbeat.com - June 23 at 9:08 AM8-K: LEAP THERAPEUTICS, INC.marketwatch.com - June 22 at 3:37 PMLeap Therapeutics, Inc.: Leap Therapeutics Announces Reverse Stock Splitfinanznachrichten.de - June 21 at 8:14 AMLeap Therapeutics Announces Reverse Stock Splitfinance.yahoo.com - June 20 at 2:45 PMRobert W. Baird Sticks to Their Buy Rating for Leap Therapeutics (LPTX)markets.businessinsider.com - May 29 at 3:34 PMLeap Therapeutics (LPTX) Receives a Buy from Mizuho Securitiesmarkets.businessinsider.com - May 26 at 2:13 AMHC Wainwright & Co. Reiterates Leap Therapeutics (LPTX) Buy Recommendationmsn.com - May 16 at 9:31 PMH.C. Wainwright Sticks to Its Buy Rating for Leap Therapeutics (LPTX)markets.businessinsider.com - May 16 at 9:33 AMAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Leap Therapeutics (LPTX) and Jasper Therapeutics (JSPR)markets.businessinsider.com - May 15 at 3:04 PMLeap Therapeutics Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 15 at 10:03 AMMizuho Reiterates Leap Therapeutics (LPTX) Buy Recommendationmsn.com - April 13 at 5:56 PMLeap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patientsfinance.yahoo.com - April 12 at 10:16 AMLeap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wiselyfinance.yahoo.com - April 4 at 12:58 PMWhat 5 Analyst Ratings Have To Say About Leap Therapeuticsmarkets.businessinsider.com - March 27 at 1:39 PMMizuho Securities Remains a Buy on Leap Therapeutics (LPTX)markets.businessinsider.com - March 24 at 2:39 PMLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Resultsfinanznachrichten.de - March 24 at 9:39 AMLeap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Resultsprnewswire.com - March 24 at 7:11 AMRobert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)markets.businessinsider.com - March 20 at 2:23 PMMizuho Securities Sticks to Its Buy Rating for Leap Therapeutics (LPTX)markets.businessinsider.com - March 16 at 11:16 PMLeap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01finance.yahoo.com - March 16 at 6:16 PMLeap Therapeutics, Inc. (LPTX)uk.finance.yahoo.com - March 16 at 1:49 AMLeap Therapeutics (NASDAQ:LPTX) PT Lowered to $3.00marketbeat.com - January 27 at 7:41 AMSHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigationsbenzinga.com - January 25 at 2:36 PMLeap Therapeutics Shares Fall After Flame Biosciences Acquisitionfinance.yahoo.com - January 25 at 9:36 AMLPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholdersbusinesswire.com - January 24 at 6:54 PMHC Wainwright Weighs in on Leap Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:LPTX)marketbeat.com - January 20 at 8:42 AMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyoutwsj.com - January 19 at 2:39 PMHC Wainwright & Co. Maintains Buy Rating for Leap Therapeutics: Here's What You Need To Knowmsn.com - January 18 at 1:47 PMLeap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conferencefinance.yahoo.com - November 21 at 9:30 AMLeap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)finance.yahoo.com - November 16 at 7:51 PMLeap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meetingfinance.yahoo.com - November 7 at 9:40 AMIs Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - October 26 at 8:48 AMLPTX Leap Therapeutics, Inc.seekingalpha.com - October 19 at 10:37 PMLeap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancerfinance.yahoo.com - October 12 at 8:54 AM Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Media Mentions By Week LPTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼1.890.74▲Average Medical News Sentiment LPTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼11▲LPTX Articles Average Week Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Tharimmune News Aclaris Therapeutics News Pyxis Oncology News Kezar Life Sciences News Spero Therapeutics News Ocuphire Pharma News InflaRx News Tiziana Life Sciences News Clearside Biomedical News Adagene News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:LPTX) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.